Former company will validate genes provided by the latter to determine functional relevance.

Alethia Biotherapeutics and Emerillon Therapeutics signed a collaborative research agreement to work together on bone-related diseases such as osteoporosis. The companies will conduct a discovery and functional validation program to identify new drug candidates.

According to the deal, Emerillon will provide a list of genetic loci that are associated with an osteoporotic phenotype in mice. In return, Alethia will generate bone-specific cDNA libraries to help identify these genes. It also will conduct cell-based validation studies to determine the functional relevance of the genes provided.

Previous articleBioSimilars Market Ripe for Expansion
Next articleMVI Awards Additional Funding to GenVec and NMRC for Malaria Vaccine Program